Health Care
Insulet delivered strong revenue growth and a net income surge in Q2 FY2026, driven by Omnipod 5 demand, though rising costs and product correction charges pressured margins.
Key risk: Manufacturing Quality and Recall Risk
The MDCs and the $29.3 million charge highlight the potential for future manufacturing issues that could lead to recalls, financial penalties, or reputational harm, impacting revenue and margins.
Other Health Care Equipment companies